CompletedNot Applicable

Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

United States61 participantsStarted 2014-12

Plain-language summary

The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Receiving a G-CSF after the institution practice change * Receiving a G-CSF for one of the following indications: * Prevention/treatment of neutropenia along with treatment for leukemia or lymphoma * Mobilization of hematopoietic progenitor cells * Neutropenia prevention following autologous hematopoietic cell transplant * Took loratadine per protocol with G-CSF administration * Completed a survey Exclusion Criteria: * Taking daily antihistamines for allergies, asthma, or other indications, not including bone pain * Taking daily NSAIDs, with the exception of aspirin, for chronic conditions * Treatment for solid tumor cancers * Receiving bone modifying agents for bone pain associated with metastatic disease or other chronic conditions

What they're measuring

Incidence of bone pain following G-CSF administration

Timeframe: Day 1

Trial details

NCT IDNCT02305979

SponsorWake Forest University Health Sciences

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-09

View on ClinicalTrials.gov More Leukemia trials